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INTRODUCTION
Fanconi anemia (FA) is one of the most prevalent inherited bone marrow failure (BMF) syndromes, caused by mutations in at least 16 different genes that are implicated in a common pathway important for genome maintenance (1,2). A hallmark of FA is cellular hypersensitivity to chemotherapeutic agents that form interstrand cross-links (ICLs). Endogenous ICLs can also arise as a result of cellular metabolism. It is thought that the FA pathway maintains genome stability by co-ordinating the necessary repair response required for the full removal of ICL lesions. Dual incision around the ICL represents a pivotal step in initiation of the repair process. A number of nucleases have been suggested to perform this critical incision event, including XPF-ERCC1 (3-6), MUS81-EME1 (7), SLX1-SLX4 (8) (9) (10) , and the Fanconi anemia Associated Nuclease 1 (FAN1) (11) (12) (13) (14) . How these nucleases are co-ordinated by the FA pathway is a very important puzzle to solve, since failed or inappropriate attempts to repair ICL lesions will result in genomic instability with increased radial formations and wide range of chromosomal abnormalities as observed in cells derived from FA patients (15) . The purpose of the proposed project is to develop biochemical systems to characterize the molecular details of ICL repair involved in genome maintenance that prevents bone marrow failure and malignant transformation.
KEYWORDS
Fanconi anemia, nucleases, interstrand cross-link repair 3. OVERALL PROJECT SUMMARY Aim 1: To explore the relationship between the nuclease proteins implicated in interstrand cross-link repair by using in vitro systems. Task 1: Further purification of proteins used in this study. Both wildtype (WT) and nuclease-dead mutant (MUT) of his-tagged FAN1 were expressed in sf9 cells and purified by Ni-NTA purification (Figure 1a ). Recombinant FAN1 obtained from this purification appears to be active, showing strong endonucleolytic activity. However, even in the mutant mutant FAN1 prep there is strong exonucleolytic activity (Figure 1b) , indicating the presence of a contaminating exonuclease in our protein prep.
Ion exchange chromatography was employed to purify the contaminant away from recombinant FAN1. The protein preps were further purified by using open columns with Q sepharose or SP sepharose beads, and nucleolytic activitiy of each fraction was examined (Figure 2 ). SP sepharose beads allowed some 32 P labeled on the strand indicated with a red asterisk. Reaction products after 30 minute incubation were subjected to denaturing PAGE.
degree of separation of FAN1 from the contaminant (Figure 2e and 2f) . However, there is partial overlap between FAN1 endonucleolytic activity and exonuleolytic activity from contaminant. This indicates that a purification system that allows greater peak resolution is required to completely purify contaminating exonuclease away. Figure 1 was further purified through Q-sepharose (a), SP-sepharose (b) then Q-sepharose (c) columns, and the input, flow through (FT) and each of the eluted fractions by increasing salt concentration were subjected to incision assays as described in Figure 2b . The left-hand panels show coomassie or silver-stained protein gels, whereas the right-hand panels show corresponding results from the incision assays. FLAG-tagged SLX4 was co-expressed with each of the three associating nucleases, SLX1, XPF-ERCC1 or MUS81-EME1 in sf9 cells and purified by anti-FLAG purification ( Figure 3 ). Both WT and MUT nucleases (Figure 3a and 3b respectively) in complex with SLX4 were purified. A significant amount of SLX4-complexes overexpressed in sf9 cells is found in the insoluble fraction, reducing the yield of soluble proteins. However, the purified protein complexes showed strong activity in nanogram scale (Figure 3c ). Similar to recombinant FAN1 purification, proteins obtained from this one-step anti-FLAG purification appear to be contaminated by exonucleases as the mutant preps also show strong exonucleolytic activity albeit being endonuclease-dead (Figure 3c ). We also employed ion exchange chromatography to test for conditions to further purify SLX4-nuclease complexes. FLAG-SLX4 alone bound strongly to Q-sepharose beads and eluted at high salt concentration (Figure 4) , suggesting that this anion-exchange matrix is an appropriate downstream step for further purification. Indeed, when we applied FALG-SLX4-HALO-tagged SLX1 through Q sepharose column, much of the exonucleolytic activity was purified away from the main fractions that contain endonycleolytic activity ( Figure 4C and 4D). Purification of SLX4 by using Q-sepharose column. FLAG-tagged SLX4 alone was first affinity-purified (a), then subjected to Q-sepharose column (b). and MUT (b) nucleases were purified by using anti-FLAG M2 resins. FLAG-SLX4-HALO-SLX1 was further purified through Q-sepharose column (c), and incision assay was performed on the eluted fractions (d).
We have recently acquired an FPLC machine through the NIH R01 grant. The FPLC machine is currently being utilized to achieve better separation of proteins in each ion exchange chromatography step. Indeed, the first FAN1 prep using the FPLC machine appears to be free of the contaminating exonuclease activity. The FPLC machine will also enable us to perform gel filtration chromatography as an additional strategy for purification, which will be particularly useful for the purification of SLX4-nuclease complexes.
Task 2: The generation of DNA interstrand cross-link substrates. DNA oligos containing modified bases for generating site-specific ICL were synthesized by Dr Ouathek Ouerfelli at the Memorial Sloan Kettering Cancer Center. The DNA oligos were designed to have different modifications at the 5' or 3' ends to allow radioactive labeling of the substrates once they are cross-linked. The oligo synthesis was initially delayed for several months due to the interference of modified bases with oligo extension and end modification. After extensive optimization, we have determined the optimal click chemistry conditions required for forming cross-links between the two oligos. By using these conditions, we are able to produce DNA ICL substrates at high efficiency that are refractory to heat denaturation (lanes 17, 19-23, 26 and 28), whereas non-crosslinked substrates that were annealed were denatured (lanes 16, 25 and 27) ( Figure 5 ). We have successfully made linear DNA duplexes (lane 2) and splayed arm (lane 4) substrates containing a single ICL. Complementary oligonucleotides are annealed to the splayed arm ICL substrates to generate 5' flap, 3' flap and replication fork substrates. We also generated splayed arm ICL substrates with ICL being placed several nucleotides away from the junction (lanes 4-8). . DNA substrates containing a site-specific interstrand cross-link. DNA oligos with modified bases were annealed and cross-linked by click chemistry. The cross-linked substrates were indicated in the schematics with a red line. Non-crosslinked oligos that were annealed were included as a control for denaturation. All substrates made were analysed by native and denaturing PAGE.
Task 3: Analysis of incision activity of nucleases.
By using nucleases purified from one step affinity purification as described in task 1, in vitro cleavage assays were performed on DNA substrates with different fork configurations to profile their substrate preferences. Recombinant FAN1 displayed strong activity on a wide range of substrates including nicked linear DNA substrates, replication fork and 5' flap substrates ( Figure 6 ). The intrinsic exonucleolytic activity of FAN1 is stronger toward single stranded DNA than double stranded DNA as more of the ssDNA products generated from endonucleolytic digestion of 5' flap substrates were degraded than the dsDNA products from replication fork substrates. The activities of purified SLX4-associated nucleases on different DNA substrates were also profiled ( Figure 7 ). All SLX4-associated nucleases displayed activity toward the top strand of splayed arm substrates with SLX4-MUS81-EME being most active. Whereas SLX4-XPF-ERCC1 only displayed activity toward splayed arm substrate, SLX4-MUS81-EME1 showed strong activity toward the top strands of 3' flap, replication fork and 5' flap. SLX4-SLX1 is active on the bottom strands of 5' flap and splayed arm substrates and the top strands of 5' flap and splayed arm substrates. None of the SLX4-associated nucleases showed activity toward the bottom strands of 3' flap and replication fork substrates. Figure 8 provides a schematic summary of the substrate specificities of the different nucleases. Task 4: Analysis of incision activity of FLAG-tagged wild type and mutant SLX4 defective in nuclease interaction immunoprecipitated from cells. I have grown up 293T cells that express tagged wild type or mutant SLX4 that does not interact with either SLX1, MUS81 or XPF. Small-scale anti-FLAG immunoprecipitation was performed on the cell extracts from these cells but the nuclease activity of the immunoprecipitated SLX4-nuclease complexes on DNA substrates appeared to be weak. Work is currently in progress to scale up the immunoprecipitation in order to obtain more active SLX4-nuclease complexes from the cells.
Aim 2:
To develop a mammalian cell free system for studying Fanconi anemia-directed ICL repair. Task 5: Development of soluble cell extract system for studying ICL repair. HeLa, U2OS, 293T cells and BJ fibroblasts have been acquired from commercial sources. In order to be able to grow up large quantities of BJ fibroblasts, we have transformed the cells with HPV16 E6E7 expression and immortalised them by expression of catalysic subunit of human telomerase. Work is currently in progress to grow up large quantities of each of the cell lines and to make soluble cell extracts. 
KEY RESEARCH ACCOMPLISHMENTS
• DNA substrates with a site-specific ICL have been successfully generated by click chemistry with high yield. The generation of such substrate by using other systems have been difficult and often with low yield. • The substrate specificity of different nucleases has been comprehensively documented.
CONCLUSION
The majority of the work during the first year has been on generating tools required for addressing the aims of the project. The progress was delayed by unexpected problems of protein insolubility, the presence of contaminating exonucleases in the protein preps and difficulty in generating DNA ICL substrates at high yield. I have spent much effort and time in scouting for optimal conditions for purifying the contaminating exonuclease away. Additionally, I have spent time on optimising conditions for generating DNA ICL substrates and have now successfully made the substrates. In order to help the progress with protein purification, the laboratory has acquired an FPLC machine. Work is currently in progress using the machine and the optimised conditions determined for purification to produce pure preps of nucleases. Once these nucleases are obtained, in vitro incision assays on the DNA substrates will be performed.
With the preliminary analyses of the activities of the different nucleases on the DNA substrates, very different substrate specificities were observed for FAN1 and SLX4-associated nucleases. This suggests that in vivo, FAN1 and SLX4-associated nucleases could have redundant roles in dealing with different DNA repair intermediates generated. Our results also showed that SLX4-MUS81-EME1 is extremely active, which is in contrast to the weak activity seen with MUS81-EME1 alone in previous studies (16) (17) (18) . It indicates that SLX4 can stimulate MUS81-EME1 activity. Most recently, our laboratory and others have reported an essential function of SLX4-MUS81-EME1 and SLX4-SLX1 in Holliday junction resolution important for faithful chromosomal segregation (19-21). The strong activity of SLX4-MUS81-EME1 on replication fork substrates observed in the current in vitro work would hint towards additional functions of SLX4-MUS81-EME1 in resolving replication intermediates and hence maintaining cell viability to prevent attrition of hematopoietic stem cells that will ultimately lead to bone marrow failure.
PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS I will attend the 26
th Annual Fanconi Anemia Research Fund Scientific Symposium in Baltimore this year to present work from this fellowship award.
INVENTIONS, PATENTS AND LICENSES
Nothing to report.
REPORTABLE OUTCOMES
OTHER ACHIEVEMENTS
• The laboratory has been awarded an NIH R01 grant, part of which is based on the work from this training award. The funding has allowed the acquisition of an FPLC machine, which will aid the purification of recombinant nucleases.
OTHER PROFESSIONAL TRAINING OPPORTUNITIES
• I attended the 25th Annual Fanconi Anemia Research Fund Scientific Symposium where I learnt the latest research progress on Fanconi anemia and presented a poster on my previous work before the current fellowship started.
• I regularly go to seminars at both the Rockefeller University and at the Memorial Sloan Kettering Cancer Center to learn the latest research techniques and progress related to the current work.
• Dr Agata Smogorzewska organises weekly journal clubs and lab meetings that provide important opportunities for keeping up to date with the latest research on Fanconi anemia and other bone marrow failure disorders. I presented every month at these meetings, which are good opportunities for developing my presentation skills.
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